Valneva SE (VALN)
NASDAQ: VALN · IEX Real-Time Price · USD
7.46
-0.25 (-3.23%)
At close: Jul 19, 2024, 4:00 PM
7.54
+0.08 (1.06%)
Pre-market: Jul 22, 2024, 6:53 AM EDT
Valneva SE Revenue
Valneva SE had revenue of $166.26M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $35.60M. In the year 2023, Valneva SE had annual revenue of $170.79M.
Revenue (ttm)
$166.26M
Revenue Growth
-58.99%
P/S Ratio
3.12
Revenue / Employee
$245,945
Employees
676
Market Cap
519.10M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 170.79M | -213.57M | -55.57% |
Dec 31, 2022 | 384.36M | -11.19M | -2.83% |
Dec 31, 2021 | 395.55M | 261.01M | 194.01% |
Dec 31, 2020 | 134.54M | -7.26M | -5.12% |
Dec 31, 2019 | 141.79M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Community Health Systems | 12.52B |
Cross Country Healthcare | 1.78B |
Sharecare | 419.82M |
Canopy Growth | 218.49M |
Y-mAbs Therapeutics | 84.50M |
Contineum Therapeutics | 50.00M |
PureTech Health | 3.33M |
VALN News
- 6 hours ago - CEPI Expands Partnership with Valneva with a $41.3 Million Grant to Support Broader Access to the World's First Chikungunya Vaccine - GlobeNewsWire
- 3 days ago - Pfizer/Valneva's Vaccine Study For Tick-Borne Infection Completes Primary Vaccination Series, Plans Approval In 2026 - Benzinga
- 4 days ago - Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion - GlobeNewsWire
- 21 days ago - Valneva Receives Marketing Authorization in Europe for the World's First Chikungunya Vaccine, IXCHIQ® - GlobeNewsWire
- 25 days ago - Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board - GlobeNewsWire
- 4 weeks ago - Valneva Announces Health Canada Approval of the World's First Chikungunya Vaccine, IXCHIQ® - GlobeNewsWire
- 6 weeks ago - Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update - GlobeNewsWire
- 6 weeks ago - Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June - GlobeNewsWire